Xeris Biopharma Holdings, Inc. 8-K

What Happened

• Xeris Biopharma Holdings, Inc. announced on April 21, 2026 (8-K filing) that Dr. Jeffrey Sherman notified the company on April 20, 2026 that he will retire from the Board and will not stand for reelection at the 2026 Annual Meeting. Dr. Sherman has served as a director since 2021 and is a member of the Compensation Committee and the Nominating and Corporate Governance Committee. His retirement is not due to any disagreement with the company or management.

Key Details

• Dr. Jeffrey Sherman provided notice of retirement on April 20, 2026; the company filed the 8-K on April 21, 2026.
• Dr. Sherman has been a director since 2021 and serves on the Compensation Committee and Nominating & Corporate Governance Committee.
• The Board approved reducing its size from eight directors to seven, effective when Dr. Sherman’s term expires at the 2026 Annual Meeting.
• Filing signed by CFO Steven M. Pieper.

Why It Matters

• Director retirements and board-size changes affect corporate governance and board composition; investors may watch for any related committee reassignments or new director nominations ahead of the annual meeting. This filing is informational and does not indicate any dispute with management.